Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Edetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | EYA2 | O00167 | 1/20 | 0.67 |
| ▸ | APP | P05067 | 1/20 | 0.67 |
| ▸ | ACE | P12821 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 2/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | DRD1 | P21728 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL2557176 | 1.00 | TDP1 (0.67) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL21793 | 1.00 | TDP1 (0.67) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL10639072 | 1.00 | TDP1 (0.67) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL3391953 | 1.00 | TDP1 (0.67) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL1132175 | 0.98 | TDP1 (0.64) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL5718746 | 0.98 | TDP1 (0.64) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL489215 | 0.98 | TDP1 (0.64) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL10706256 | 0.98 | TDP1 (0.64) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL153915 | 0.94 | TDP1 (0.58) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL3391944 | 0.94 | TDP1 (0.58) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586086-B2 | Hydrogel capable of containing and conveying cells | POLITECNICO DI MILANO (IT) | 2013-11-19 | — | — | US | disclosed |
| US-8143204-B2 | Removal or prevention scale formation; using soluble magnesium salts; preinjection before evaporation | ECOLAB USA INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110236367-A1 | RAT CATHESPIN DIPEPTIDYL PEPTIDASE I (DPPI): CRYSTAL STRUCTURE AND ITS USES | TELENAV, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110189285-A1 | HYDROGEL CAPABLE OF CONTAINING AND CONVEYING CELLS | POLITECNICO DI MILANO (IT) | 2011-08-04 | — | — | US | disclosed |
| WO-2011082064-A1 | CHELATING AGENT MODIFIED GRAPHENE OXIDES, METHODS OF PREPARATION AND USE | MONTCLAIR STATE UNIVERSITY (US) | 2011-07-07 | — | — | WO | disclosed |
| US-7939498-B2 | Cyclic peptides for preserving or enhancing the function of an organ allograft | BRITISH CANADIAN BIOSCIENCES CORP. (CA) | 2011-05-10 | — | — | US | disclosed |
| EP-2296616-A1 | A PERSONAL WASH COMPOSITION | Unilever N.V. (NL) | 2011-03-23 | — | — | EP | disclosed |
| EP-2293775-A2 | HYDROGEL CAPABLE OF CONTAINING AND CONVEYING CELLS | Politecnico di Milano (IT) | 2011-03-16 | — | — | EP | disclosed |
| WO-2009144569-A2 | HYDROGEL CAPABLE OF CONTAINING AND CONVEYING CELLS | POLITECNICO DI MILANO (IT) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110236367-A1 | RAT CATHESPIN DIPEPTIDYL PEPTIDASE I (DPPI): CRYSTAL STRUCTURE AND ITS USES | DPP3, DPP7, DPP4 | ADRA2A 4471/4885TDP1 1401/4885EYA2 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.